James R Porter

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90

Jie Ge, James R. Porter, J. Sydor, 2006, Proceedings of the National Academy of Sciences.

PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.

Bonnie Tillotson, James R. Porter, Pingda Ren, 2013, Chemistry & biology.